Viridian Therapeutics, Inc

(NASDAQ:MGEN)

Latest On Viridian Therapeutics, Inc (MGEN):

Date/Time Type Description Signal Details
2021-01-19 14:55 ESTNewsmiRagen Therapeutics changes name to Viridian; announces leadership changesN/A
2021-01-06 16:09 ESTFinancialsCompany financials have been released.Neutral
2021-01-01 12:14 ESTAnalyst RatingThe Analyst Target Price has decreased from $41 to $31.5.Neutral
2020-12-17 20:33 ESTNewsMiragen Therapeutics enters license pact with Xencor for Xtend technology to treat thyroid eye diseaseN/A
2020-12-16 12:28 ESTAnalyst RatingThe Analyst Target Price has increased from $40 to $41.Buy
2020-12-09 03:15 ESTNewsMiragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry OpportunityN/A
2020-11-27 12:32 ESTAnalyst RatingThe Analyst Target Price has decreased from $54 to $40.Neutral
2020-11-26 20:48 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 12:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $75 to $54.Neutral
2020-11-17 04:41 ESTAnalyst RatingThe Analyst Target Price has increased from $5 to $75.Buy
2020-11-15 04:32 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 04:41 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 20:57 ESTEarnings EstimateAn EPS average of -$0.10 is estimated for the quarter ending on March 31, 2021.N/A
2020-11-10 19:22 ESTNewsMiragen Therapeutics EPS beats by $0.03N/A
2020-11-07 16:27 ESTFinancialsCompany financials have been released.Neutral
2020-10-31 21:10 ESTNewsMiRagen Therapeutics shares skyrocket 156% on Viridian acquisition, inks PIPE deal for $91MN/A
2020-10-30 13:47 ESTAnalyst RatingThe Analyst Target Price has decreased from $5.2 to $5.Neutral
2020-10-06 16:56 ESTNewsMiRagen's cobomarsen short of the mark in mid-stage blood cancer studyN/A
2020-09-26 13:22 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:29 ESTFinancialsCompany financials have been released.Neutral
2020-09-15 19:59 ESTNewsmiRagen names new CEO; to review portfolioN/A
2020-08-26 01:13 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:26 ESTFinancialsCompany financials have been released.Neutral
2020-08-08 01:14 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 21:44 ESTNewsmiRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-05 18:52 ESTNewsMiragen Therapeutics EPS beats by $0.05, misses on revenueN/A
2020-07-31 01:38 ESTFinancialsCompany financials have been released.Neutral
2020-07-24 06:21 ESTNewsmiRagen Therapeutics up 39% on Orphan Drug tag for Cobomarsen in blood cancerN/A
2020-07-23 17:43 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 17:43 ESTAnalyst RatingThe Analyst Target Price has increased from $5 to $5.2.Buy
2020-07-09 09:20 ESTFinancialsCompany financials have been released.Neutral
2020-07-07 09:03 ESTAnalyst RatingThe Analyst Target Price has increased from $4.2 to $5.Buy
2020-07-03 14:11 ESTNewsmiRagen Therapeutics regains Nasdaq complianceN/A
2020-06-26 09:19 ESTFinancialsCompany financials have been released.Neutral
2020-06-18 18:52 ESTNewsNew operating chief at miRagen TherapeuticsN/A
2020-06-17 12:39 ESTNewsMiRagen to host KOL event on ideopathic pulmonary fibrosis June 23N/A
2020-06-12 05:24 ESTFinancialsCompany financials have been released.Neutral
2020-06-04 07:56 ESTNewsMiragen Therapeutics (MGEN) Presents At Jefferies Healthcare Conference - SlideshowN/A
2020-06-02 09:08 ESTEarnings EstimateAn EPS average of -$0.15 is estimated for the quarter ending on September 30, 2020.Buy
2020-06-02 09:08 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.8 to $4.2.Neutral
2020-05-27 05:30 ESTFinancialsCompany financials have been released.Neutral
2020-05-15 20:54 ESTFinancialsCompany financials have been released.Neutral
2020-05-10 17:34 ESTFinancialsCompany financials have been released.Neutral
2020-05-10 04:44 ESTNewsMiragen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q1 2020 Results - Earnings Call TranscriptN/A
2020-05-08 02:13 ESTNewsMiragen Therapeutics EPS beats by $0.03, beats on revenueN/A
2020-05-06 05:35 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 05:08 ESTFinancialsCompany financials have been released.Neutral
2020-04-12 02:12 ESTNewsMiragen Therapeutics EPS misses by $0.06, beats on revenueN/A
2020-04-12 01:55 ESTNewsMiragen Therapeutics files for $175M mixed shelfN/A
2020-04-03 01:17 ESTFinancialsCompany financials have been released.Neutral

About Viridian Therapeutics, Inc (MGEN):

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

MGEN Quotes by TradingView

See Advanced Chart

General

  • Name Viridian Therapeutics, Inc
  • Symbol MGEN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 45
  • Last Split Factor1:15
  • Last Split Date2020-11-13
  • Fiscal Year EndDecember
  • IPO Date2014-06-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.miragen.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 36.14
  • Price/Book (Most Recent Quarter) 4.05
  • Enterprise Value Revenue 34.26
  • Enterprise Value EBITDA 0.03
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.13
  • Operating Margin -1469%
  • Return on Assets -48%
  • Return on Equity -136%
  • Revenue 1.88 million
  • Earnings Per Share -$1.29
  • Revenue Per Share $0.6
  • Gross Profit -28633000
  • Quarterly Earnings Growth -93.3%
View More

Highlights

  • Market Capitalization 89.93 million
  • EBITDA -39995000
  • Analyst Target Price $31.5
  • Book Value Per Share $5.53
View More

Share Statistics

  • Shares Outstanding 3.91 million
  • Shares Float 1.46 million
  • % Held by Insiders 17%
  • % Held by Institutions 55.33%
  • Shares Short 133760
  • Shares Short Prior Month 161699
  • Short Ratio 1.56
  • Short % of Float 5%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.32
  • 52 Week High $25.67
  • 52 Week Low $5.51
  • 50 Day Moving Average 19.64
  • 200 Day Moving Average 16
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Viridian Therapeutics, Inc (MGEN) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Viridian Therapeutics, Inc (MGEN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-10$N/A-$1.50-$1.9924.53%
2020-06-302020-08-05$N/A-$1.80-$2.4827.27%
2020-03-312020-05-07$828000-$2.70-$3.1514.29%
2019-12-312020-03-11$880000-$4.65-$3.78-23.02%
2019-09-302019-11-07$N/A-$5.40-$4.44-21.62%
2019-06-302019-08-07$2.51 million-$4.35-$5.4520.18%
2019-03-312019-05-08$372000-$5.70-$5.16-10.47%
2018-12-312019-03-13$476000-$4.95-$4.62-7.14%
2018-09-302018-11-07$944000-$4.35-$4.768.66%
2018-06-302018-08-07$2.18 million-$4.35-$4.350%
2018-03-312018-05-09$4.78 million-$2.70-$3.6726.46%
2017-12-312018-03-14$1.19 million-$4.35-$4.768.66%
2017-09-302017-11-08$1.63 million-$4.05-$5.7028.95%
2017-06-302017-08-11$718000-$5.10-$7.0527.66%
2017-03-312017-05-10$462000-$9.00-$3.60-150%
2016-12-312017-03-31$756000-$4.08-$3.45-18.26%
2016-09-302016-10-26$889000-$2.56
2016-06-302016-08-15$874000-$3.45-$2.77-24.55%
2016-03-312016-05-16$818000-$3.90-$4.207.14%
2015-12-312016-03-16$658000-$4.20-$5.4022.22%
2015-09-302015-11-12$501000-$5.85-$5.55-5.41%
2015-06-302015-08-12$734000-$4.95-$5.8515.38%
2015-03-312015-05-14$645000-$6.75-$5.40-25%
2014-12-312015-03-30-$25.80-$5.85-341.03%
2014-09-302014-11-14$1.3 million-$0.43-$0.05-760%
2014-06-302014-08-08$1.27 million-$16.99

Viridian Therapeutics, Inc (MGEN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Viridian Therapeutics, Inc (MGEN) Chart:

Viridian Therapeutics, Inc (MGEN) News:

Below you will find a list of latest news for Viridian Therapeutics, Inc (MGEN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Viridian Therapeutics, Inc (MGEN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Viridian Therapeutics, Inc (MGEN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000071/0001590750-20-000071-index.htm
2020-04-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1590750/000000000020002800/0000000000-20-002800-index.htm
2018-11-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1590750/000031506618002478/0000315066-18-002478-index.htm
2020-10-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1590750/000089914020000495/0000899140-20-000495-index.htm
2020-10-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029563/0000899243-20-029563-index.htm
2020-10-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029564/0000899243-20-029564-index.htm
2020-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029660/0000899243-20-029660-index.htm
2020-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029699/0000899243-20-029699-index.htm
2020-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029702/0000899243-20-029702-index.htm
2020-10-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029902/0000899243-20-029902-index.htm
2020-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029904/0000899243-20-029904-index.htm
2020-10-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029993/0000899243-20-029993-index.htm
2020-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000089924320029996/0000899243-20-029996-index.htm
2019-01-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1590750/000092189519000005/0000921895-19-000005-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1590750/000101359420000120/0001013594-20-000120-index.htm
2018-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518064001/0001193125-18-064001-index.htm
2018-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518082316/0001193125-18-082316-index.htm
2018-03-15S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1590750/000119312518082992/0001193125-18-082992-index.htm
2018-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518096614/0001193125-18-096614-index.htm
2018-03-278-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518096752/0001193125-18-096752-index.htm
2018-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518109192/0001193125-18-109192-index.htm
2018-04-2010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1590750/000119312518125053/0001193125-18-125053-index.htm
2018-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518136623/0001193125-18-136623-index.htm
2018-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518148704/0001193125-18-148704-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518156004/0001193125-18-156004-index.htm
2018-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518157540/0001193125-18-157540-index.htm
2018-05-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1590750/000119312518164110/0001193125-18-164110-index.htm
2018-05-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1590750/000119312518164130/0001193125-18-164130-index.htm
2018-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518182519/0001193125-18-182519-index.htm
2018-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518207631/0001193125-18-207631-index.htm
2018-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518215092/0001193125-18-215092-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518239694/0001193125-18-239694-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518241057/0001193125-18-241057-index.htm
2018-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518288544/0001193125-18-288544-index.htm
2018-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518340366/0001193125-18-340366-index.htm
2018-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518342966/0001193125-18-342966-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312518353840/0001193125-18-353840-index.htm
2019-03-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1590750/000119312519074803/0001193125-19-074803-index.htm
2019-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312519120846/0001193125-19-120846-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312519123670/0001193125-19-123670-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312519152212/0001193125-19-152212-index.htm
2019-07-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312519197230/0001193125-19-197230-index.htm
2019-12-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1590750/000119312519312775/0001193125-19-312775-index.htm
2020-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312520026768/0001193125-20-026768-index.htm
2020-02-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1590750/000119312520026925/0001193125-20-026925-index.htm
2020-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312520027538/0001193125-20-027538-index.htm
2020-02-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1590750/000119312520028285/0001193125-20-028285-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312520041911/0001193125-20-041911-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312520198117/0001193125-20-198117-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312520248159/0001193125-20-248159-index.htm
2020-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000119312520279263/0001193125-20-279263-index.htm
2018-02-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118012719/0001209191-18-012719-index.htm
2018-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118039868/0001209191-18-039868-index.htm
2018-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118039875/0001209191-18-039875-index.htm
2018-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118039879/0001209191-18-039879-index.htm
2018-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118039883/0001209191-18-039883-index.htm
2018-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118039887/0001209191-18-039887-index.htm
2018-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118039891/0001209191-18-039891-index.htm
2018-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118039897/0001209191-18-039897-index.htm
2018-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118046026/0001209191-18-046026-index.htm
2018-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118048029/0001209191-18-048029-index.htm
2018-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118048033/0001209191-18-048033-index.htm
2018-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118048036/0001209191-18-048036-index.htm
2018-10-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919118054894/0001209191-18-054894-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119008515/0001209191-19-008515-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119008530/0001209191-19-008530-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119008536/0001209191-19-008536-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119008542/0001209191-19-008542-index.htm
2019-04-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119023845/0001209191-19-023845-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119038556/0001209191-19-038556-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119038561/0001209191-19-038561-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119038565/0001209191-19-038565-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119038570/0001209191-19-038570-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119038573/0001209191-19-038573-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119038579/0001209191-19-038579-index.htm
2019-08-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119047367/0001209191-19-047367-index.htm
2019-12-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919119061177/0001209191-19-061177-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120009420/0001209191-20-009420-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120009783/0001209191-20-009783-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120009786/0001209191-20-009786-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120009789/0001209191-20-009789-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120019580/0001209191-20-019580-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120031816/0001209191-20-031816-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120031825/0001209191-20-031825-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120031830/0001209191-20-031830-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120031835/0001209191-20-031835-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120031837/0001209191-20-031837-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120031843/0001209191-20-031843-index.htm
2020-06-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120039032/0001209191-20-039032-index.htm
2020-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120048264/0001209191-20-048264-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120050617/0001209191-20-050617-index.htm
2020-09-174/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000120919120050986/0001209191-20-050986-index.htm
2020-03-26S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1590750/000156459020013253/0001564590-20-013253-index.htm
2018-03-1510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1590750/000159075018000006/0001590750-18-000006-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1590750/000159075018000012/0001590750-18-000012-index.htm
2018-08-06DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000159075018000015/0001590750-18-000015-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1590750/000159075018000018/0001590750-18-000018-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075018000025/0001590750-18-000025-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1590750/000159075018000027/0001590750-18-000027-index.htm
2019-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000002/0001590750-19-000002-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000004/0001590750-19-000004-index.htm
2019-02-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000006/0001590750-19-000006-index.htm
2019-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1590750/000159075019000013/0001590750-19-000013-index.htm
2019-05-03DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000021/0001590750-19-000021-index.htm
2019-05-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000023/0001590750-19-000023-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000030/0001590750-19-000030-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1590750/000159075019000032/0001590750-19-000032-index.htm
2019-06-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000035/0001590750-19-000035-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000040/0001590750-19-000040-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1590750/000159075019000042/0001590750-19-000042-index.htm
2019-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000045/0001590750-19-000045-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000051/0001590750-19-000051-index.htm
2019-10-31D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000052/0001590750-19-000052-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000056/0001590750-19-000056-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1590750/000159075019000059/0001590750-19-000059-index.htm
2019-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075019000063/0001590750-19-000063-index.htm
2020-01-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000005/0001590750-20-000005-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000015/0001590750-20-000015-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1590750/000159075020000021/0001590750-20-000021-index.htm
2020-03-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000023/0001590750-20-000023-index.htm
2020-03-27PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000026/0001590750-20-000026-index.htm
2020-04-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000034/0001590750-20-000034-index.htm
2020-04-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000035/0001590750-20-000035-index.htm
2020-04-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000036/0001590750-20-000036-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000042/0001590750-20-000042-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000050/0001590750-20-000050-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1590750/000159075020000053/0001590750-20-000053-index.htm
2020-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000058/0001590750-20-000058-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000063/0001590750-20-000063-index.htm
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000068/0001590750-20-000068-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000071/0001590750-20-000071-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000080/0001590750-20-000080-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1590750/000159075020000082/0001590750-20-000082-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000085/0001590750-20-000085-index.htm
2020-10-018-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000088/0001590750-20-000088-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000092/0001590750-20-000092-index.htm
2020-10-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000095/0001590750-20-000095-index.htm
2020-11-06DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1590750/000159075020000096/0001590750-20-000096-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1590750/000162828019002862/0001628280-19-002862-index.htm
2020-04-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1590750/999999999520000749/9999999995-20-000749-index.htm
2018-05-22CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1590750/999999999718005813/9999999997-18-005813-index.htm
2018-08-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1590750/999999999718007349/9999999997-18-007349-index.htm
2018-11-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1590750/999999999718009039/9999999997-18-009039-index.htm
2019-07-03SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1590750/999999999719006059/9999999997-19-006059-index.htm
2019-07-11SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1590750/999999999719006096/9999999997-19-006096-index.htm
2020-02-06SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1590750/999999999720000562/9999999997-20-000562-index.htm
2020-02-18SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1590750/999999999720000777/9999999997-20-000777-index.htm

Viridian Therapeutics, Inc (MGEN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Viridian Therapeutics, Inc (MGEN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 17%
Institutional Ownership: 5533%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-10-11Thomas E. HughesDirectorBuy10,000.004.7747,697.0012,827.00https://www.sec.gov/Archives/edgar/data/1590750/000120919118054894/0001209191-18-054894-index.htm
2018-08-07Jason A. LeveroneCFO, Treasurer & SecretaryBuy29,530.000.5716,832.1030,737.00https://www.sec.gov/Archives/edgar/data/1590750/000120919118046026/0001209191-18-046026-index.htm
2019-08-23Jason A. LeveroneCFO, Treasurer & SecretaryBuy3,093.000.571,763.0136,330.00https://www.sec.gov/Archives/edgar/data/1590750/000120919119047367/0001209191-19-047367-index.htm
2020-03-13Jason A. LeveroneCFO, Treasurer & SecretaryBuy11,249.000.576,411.9348,829.00https://www.sec.gov/Archives/edgar/data/1590750/000120919120019580/0001209191-20-019580-index.htm